AN ACT
relating to the administration and oversight of investigational
adult stem cell treatments administered to certain patients.

BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF TEXAS:
SECTION 1. Subchapter B, Chapter 1003, Health and Safety
Code, is amended by adding Sections 1003.0525 and 1003.0526 to read
as follows:

Sec. 1003.0525. ADMINISTRATION OF SUBCHAPTER. The
department shall administer this subchapter.

Sec. 1003.0526. INVESTIGATIONAL STEM CELL REGISTRY. The
department shall establish and maintain an investigational stem
cell registry that lists each physician who administers an
investigational stem cell treatment under this subchapter.

SECTION 2. Section 1003.054(c), Health and Safety Code, is
amended to read as follows:

(c) The executive commissioner by rule shall [may] adopt a
form for the informed consent under this section. The form must
provide notice that the department administers this subchapter.

SECTION 3. Section 1003.055(d), Health and Safety Code, is
amended to read as follows:

(d) An institutional review board that oversees
investigational stem cell treatments administered under this
subchapter must meet one of the following conditions [be affiliated
with]:

1
be affiliated with a medical school, as defined by Section 61.501, Education Code; [or
be affiliated with a hospital licensed under Chapter 241 that has at least 150 beds;]
be accredited by the Association for the Accreditation of Human Research Protection Programs;
be registered by the United States Department of Health and Human Services, Office for Human Research Protections, in accordance with 21 C.F.R. Part 56; or
be accredited by a national accreditation organization acceptable to the Texas Medical Board.

SECTION 4. Section 1003.058(b), Health and Safety Code, is amended to read as follows:
(b) A governmental entity or an officer, employee, or agent of a governmental entity may not interfere with an eligible patient's access to or use of an investigational [stem] cell treatment authorized under this subchapter unless the treatment uses an adult stem cell product that is considered an adulterated or misbranded drug under Chapter 431. For purposes of this subsection, a governmental entity may not consider the adult stem cell product to be an adulterated or misbranded drug solely on the basis that the United States Food and Drug Administration has not approved the adult stem cell product.

SECTION 5. Subchapter B, Chapter 1003, Health and Safety Code, is amended by adding Section 1003.060 to read as follows:
Sec. 1003.060. CONSTRUCTION OF SUBCHAPTER. This subchapter may not be construed to:
H.B. No. 3148

(1) prohibit a physician from using adult stem cells for their intended homologous use if the stem cells are:

(A) produced by a manufacturer registered by the United States Food and Drug Administration; and

(B) commercially available; or

(2) require an institutional review board to oversee treatment using adult stem cells registered by the United States Food and Drug Administration for their intended homologous use.

SECTION 6. The Department of State Health Services may not establish the investigational stem cell registry described by Section 1003.0526, Health and Safety Code, as added by this Act, until September 1, 2027.

SECTION 7. This Act takes effect September 1, 2019.
I certify that H.B. No. 3148 was passed by the House on May 9, 2019, by the following vote: Yeas 141, Nays 0, 2 present, not voting; that the House refused to concur in Senate amendments to H.B. No. 3148 on May 23, 2019, and requested the appointment of a conference committee to consider the differences between the two houses; and that the House adopted the conference committee report on H.B. No. 3148 on May 26, 2019, by the following vote: Yeas 141, Nays 0, 3 present, not voting.
H.B. No. 3148

I certify that H.B. No. 3148 was passed by the Senate, with amendments, on May 21, 2019, by the following vote: Yeas 31, Nays 0; at the request of the House, the Senate appointed a conference committee to consider the differences between the two houses; and that the Senate adopted the conference committee report on H.B. No. 3148 on May 26, 2019, by the following vote: Yeas 31, Nays 0.

________________________________________
Secretary of the Senate

APPROVED: _____________________________
                      Date

________________________________________
Governor